Sander Idema
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Interests
Sander Idema has a total of 200 co-authors. Here are the top co-authors by number of shared publications:
- Martine L. M. Lamfers
Department of Neurosurgery, Brain Tumor Center, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, Netherlands
5 shared publications W. Peter Vandertop
Academic Medical Center Amsterdam, Amsterdam, The Netherlands; VU University Medical Center, Neurosurgical Center Amsterdam, Amsterdam, The Netherlands
4 shared publicationsDavid P. Noske
Neurosurgical Center Amsterdam and Cancer Center Amsterdam, Neuro-oncology Research Group, VU University Medical Center, Amsterdam, The Netherlands
3 shared publications- Johannes C. Baayen
Department of Neurosurgery, VU medical center (VUmc), Amsterdam, The Netherlands
3 shared publications Victor W. van Beusechem
Section Oncogenomics, Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
3 shared publications- Amber Kerkhofs
Department of Integrative Neurophysiology, Amsterdam Neuroscience, Center for Neurogenomics and Cognitive Research (CNCR), Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
2 shared publications
Latest Publications
- Open Access
- 18 December 2018
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 7
Large and fast human pyramidal neurons associate with intelligence
It is generally assumed that human intelligence relies on efficient processing by neurons in our brain. Although grey matter thickness and activity of temporal and frontal cortical areas correlate with IQ scores, no direct evidence exists that links structural and physiological properties of neurons to human intelligence. Here, we find that high IQ scores and large temporal cortical thickness associate with larger, more complex dendrites of human pyramidal neurons. We show in silico that larger dendritic trees enable pyramidal neurons to track activity of synaptic inputs with higher temporal precision, due to fast action potential kinetics. Indeed, we find that human pyramidal neurons of individuals with higher IQ scores sustain fast action potential kinetics during repeated firing. These findings provide the first evidence that human intelligence is associated with neuronal complexity, action potential kinetics and efficient information transfer from inputs to output within cortical neurons.
- 18 December 2018
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 7
Open AccessLarge and fast human pyramidal neurons associate with intelligence
It is generally assumed that human intelligence relies on efficient processing by neurons in our brain. Although grey matter thickness and activity of temporal and frontal cortical areas correlate with IQ scores, no direct evidence exists that links structural and physiological properties of neurons to human intelligence. Here, we find that high IQ scores and large temporal cortical thickness associate with larger, more complex dendrites of human pyramidal neurons. We show in silico that larger dendritic trees enable pyramidal neurons to track activity of synaptic inputs with higher temporal precision, due to fast action potential kinetics. Indeed, we find that human pyramidal neurons of individuals with higher IQ scores sustain fast action potential kinetics during repeated firing. These findings provide the first evidence that human intelligence is associated with neuronal complexity, action potential kinetics and efficient information transfer from inputs to output within cortical neurons.
- Open Access
- 21 July 2018
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 15 (1) , 1-14
Increased expression of matrix metalloproteinase 3 can be attenuated by inhibition of microRNA-155 in cultured human astrocytes
Temporal lobe epilepsy (TLE) is a chronic neurological disease, in which about 30% of patients cannot be treated adequately with anti-epileptic drugs. Brain inflammation and remodeling of the extracellular matrix (ECM) seem to play a major role in TLE. Matrix metalloproteinases (MMPs) are proteolytic enzymes largely responsible for the remodeling of the ECM. The inhibition of MMPs has been suggested as a novel therapy for epilepsy; however, available MMP inhibitors lack specificity and cause serious side effects. We studied whether MMPs could be modulated via microRNAs (miRNAs). Several miRNAs mediate inflammatory responses in the brain, which are known to control MMP expression. The aim of this study was to investigate whether an increased expression of MMPs after interleukin-1β (IL-1β) stimulation can be attenuated by inhibition of the inflammation-associated miR-155. We investigated the expression of MMP2, MMP3, MMP9, and MMP14 in cultured human fetal astrocytes after stimulation with the pro-inflammatory cytokine IL-1β. The cells were transfected with miR-155 antagomiR, and the effect on MMP3 expression was investigated using real-time quantitative PCR and Western blotting. Furthermore, we characterized MMP3 and miR-155 expression in brain tissue of TLE patients with hippocampal sclerosis (TLE-HS) and during epileptogenesis in a rat TLE model. Inhibition of miR-155 by the antagomiR attenuated MMP3 overexpression after IL-1β stimulation in astrocytes. Increased expression of MMP3 and miR-155 was also evident in the hippocampus of TLE-HS patients and throughout epileptogenesis in the rat TLE model. Our experiments showed that MMP3 is dynamically regulated by seizures as shown by increased expression in TLE tissue and during different phases of epileptogenesis in the rat TLE model. MMP3 can be induced by the pro-inflammatory cytokine IL-1β and is regulated by miR-155, suggesting a possible strategy to prevent epilepsy via reduction of inflammation.
- 21 July 2018
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 15 (1) , 1-14
Open AccessIncreased expression of matrix metalloproteinase 3 can be attenuated by inhibition of microRNA-155 in cultured human astrocytes
Temporal lobe epilepsy (TLE) is a chronic neurological disease, in which about 30% of patients cannot be treated adequately with anti-epileptic drugs. Brain inflammation and remodeling of the extracellular matrix (ECM) seem to play a major role in TLE. Matrix metalloproteinases (MMPs) are proteolytic enzymes largely responsible for the remodeling of the ECM. The inhibition of MMPs has been suggested as a novel therapy for epilepsy; however, available MMP inhibitors lack specificity and cause serious side effects. We studied whether MMPs could be modulated via microRNAs (miRNAs). Several miRNAs mediate inflammatory responses in the brain, which are known to control MMP expression. The aim of this study was to investigate whether an increased expression of MMPs after interleukin-1β (IL-1β) stimulation can be attenuated by inhibition of the inflammation-associated miR-155. We investigated the expression of MMP2, MMP3, MMP9, and MMP14 in cultured human fetal astrocytes after stimulation with the pro-inflammatory cytokine IL-1β. The cells were transfected with miR-155 antagomiR, and the effect on MMP3 expression was investigated using real-time quantitative PCR and Western blotting. Furthermore, we characterized MMP3 and miR-155 expression in brain tissue of TLE patients with hippocampal sclerosis (TLE-HS) and during epileptogenesis in a rat TLE model. Inhibition of miR-155 by the antagomiR attenuated MMP3 overexpression after IL-1β stimulation in astrocytes. Increased expression of MMP3 and miR-155 was also evident in the hippocampus of TLE-HS patients and throughout epileptogenesis in the rat TLE model. Our experiments showed that MMP3 is dynamically regulated by seizures as shown by increased expression in TLE tissue and during different phases of epileptogenesis in the rat TLE model. MMP3 can be induced by the pro-inflammatory cytokine IL-1β and is regulated by miR-155, suggesting a possible strategy to prevent epilepsy via reduction of inflammation.
- Open Access
Large and fast human pyramidal neurons associate with intelligence
It is generally assumed that human intelligence relies on efficient processing by neurons in our brain. Behavioral and brain-imaging studies robustly show that higher intelligence associates with faster reaction times and thicker gray matter in temporal and frontal cortical areas. However, no direct evidence exists that links individual neuron activity and structure to human intelligence. Since a large part of cortical grey matter consists of dendrites, these structures likely determine cortical architecture. In addition, dendrites strongly affect functional properties of neurons, including action potential speed. Thereby, dendritic size and action potential firing may constitute variation in cortical thickness, processing speed, and ultimately IQ. To investigate this, we took advantage of brain tissue available from neurosurgery and recorded from pyramidal neurons in the medial temporal cortex, an area showing high association between cortical thickness, cortical activity and intelligence. Next, we reconstructed full dendritic structures of recorded neurons and combined these with brain-imaging data and IQ scores from the same subjects. We find that high IQ scores and large temporal cortical thickness associate with larger, more complex dendrites of human pyramidal neurons. We show in silico that larger dendrites enable pyramidal neurons to track activity of synaptic inputs with higher temporal precision, due to fast action potential initiation. Finally, we find that human pyramidal neurons of individuals with higher IQ scores sustain faster action potentials during repeated firing. These findings provide first evidence that human intelligence is associated with neuronal complexity, action potential speed and efficient information transfer in cortical neurons.
Open AccessLarge and fast human pyramidal neurons associate with intelligence
It is generally assumed that human intelligence relies on efficient processing by neurons in our brain. Behavioral and brain-imaging studies robustly show that higher intelligence associates with faster reaction times and thicker gray matter in temporal and frontal cortical areas. However, no direct evidence exists that links individual neuron activity and structure to human intelligence. Since a large part of cortical grey matter consists of dendrites, these structures likely determine cortical architecture. In addition, dendrites strongly affect functional properties of neurons, including action potential speed. Thereby, dendritic size and action potential firing may constitute variation in cortical thickness, processing speed, and ultimately IQ. To investigate this, we took advantage of brain tissue available from neurosurgery and recorded from pyramidal neurons in the medial temporal cortex, an area showing high association between cortical thickness, cortical activity and intelligence. Next, we reconstructed full dendritic structures of recorded neurons and combined these with brain-imaging data and IQ scores from the same subjects. We find that high IQ scores and large temporal cortical thickness associate with larger, more complex dendrites of human pyramidal neurons. We show in silico that larger dendrites enable pyramidal neurons to track activity of synaptic inputs with higher temporal precision, due to fast action potential initiation. Finally, we find that human pyramidal neurons of individuals with higher IQ scores sustain faster action potentials during repeated firing. These findings provide first evidence that human intelligence is associated with neuronal complexity, action potential speed and efficient information transfer in cortical neurons.
- 1 July 2014
- Published by Elsevier in World Neurosurgery
- Vol. 82 (1-2) , e376-e377
Standardization of Surgical Procedures: Beyond Checklists?
- 1 July 2014
- Published by Elsevier in World Neurosurgery
- Vol. 82 (1-2) , e376-e377
Standardization of Surgical Procedures: Beyond Checklists?
- 13 March 2013
- Published by Wiley in The Journal of Gene Medicine
- Vol. 15 (3-4) , 134-141
Therapeutic concentrations of anti‐epileptic drugs do not inhibit the activity of the oncolytic adenovirus Delta24‐RGD in malignant glioma
Background The oncolytic adenovirus Delta24-RGD is currently being tested in phase I trials for the treatment of glioblastoma (GBM). Literature suggests that frequently prescribed anticonvulsants for these patients, phenytoin (PHE), valproic acid (VPA) and levetiracetam (LEV), may interfere with cellular mechanisms of cancer or oncolytic virus activity. We therefore investigated the direct effects of these drugs on Delta24-RGD infection and oncolytic activity. Methods The anticonvulsants PHE, VPA, and LEV were combined with Delta24-RGD treatment in established glioma cell lines as well as on a panel of patient-derived GBM cultures. Effects on infection efficiency were assessed using luciferase-encoding adenoviral vectors. Oncolytic activity was determined by WST-1 assay and viral progeny production was quantified by dilution titration. Results IC50 values of the anti-epileptic drugs on the four glioma cell lines were far above clinically-relevant concentrations. At therapeutic concentrations, the anti-epileptics generally did not alter the infection efficiency of RGD-modified adenovirus, nor affect progeny production or oncolytic activity of Delta24-RGD. The only exception was found in U373 cells, where VPA slightly antagonised the oncolytic effect of Delta24-RGD (from 29% to 55% viability, p<0.01) as well as viral progeny production (60% decrease, p<0.01). Oncolysis by Delta24-RGD was not inhibited by the anti-epileptics in any of the patient-derived glioma cultures (n=6). In fact, in one culture a slight enhancement of viral oncolysis by PHE and LEV was found, from 89.7% viability to 76% and 62.4%, respectively (p<0.01) Conclusions Therapeutic levels of valproic acid, phenytoin and levetiracetam do not negatively interfere with the infection efficiency or oncolytic activity of Delta24-RGD in patient-derived GBM cells. Therefore, there is no indication that the choice of anticonvulsant for seizure control in glioma patients should take treatment with Delta24-RGD into account. Copyright © 2013 John Wiley & Sons, Ltd.
- 13 March 2013
- Published by Wiley in The Journal of Gene Medicine
- Vol. 15 (3-4) , 134-141
Therapeutic concentrations of anti‐epileptic drugs do not inhibit the activity of the oncolytic adenovirus Delta24‐RGD in malignant glioma
Background The oncolytic adenovirus Delta24-RGD is currently being tested in phase I trials for the treatment of glioblastoma (GBM). Literature suggests that frequently prescribed anticonvulsants for these patients, phenytoin (PHE), valproic acid (VPA) and levetiracetam (LEV), may interfere with cellular mechanisms of cancer or oncolytic virus activity. We therefore investigated the direct effects of these drugs on Delta24-RGD infection and oncolytic activity. Methods The anticonvulsants PHE, VPA, and LEV were combined with Delta24-RGD treatment in established glioma cell lines as well as on a panel of patient-derived GBM cultures. Effects on infection efficiency were assessed using luciferase-encoding adenoviral vectors. Oncolytic activity was determined by WST-1 assay and viral progeny production was quantified by dilution titration. Results IC50 values of the anti-epileptic drugs on the four glioma cell lines were far above clinically-relevant concentrations. At therapeutic concentrations, the anti-epileptics generally did not alter the infection efficiency of RGD-modified adenovirus, nor affect progeny production or oncolytic activity of Delta24-RGD. The only exception was found in U373 cells, where VPA slightly antagonised the oncolytic effect of Delta24-RGD (from 29% to 55% viability, p<0.01) as well as viral progeny production (60% decrease, p<0.01). Oncolysis by Delta24-RGD was not inhibited by the anti-epileptics in any of the patient-derived glioma cultures (n=6). In fact, in one culture a slight enhancement of viral oncolysis by PHE and LEV was found, from 89.7% viability to 76% and 62.4%, respectively (p<0.01) Conclusions Therapeutic levels of valproic acid, phenytoin and levetiracetam do not negatively interfere with the infection efficiency or oncolytic activity of Delta24-RGD in patient-derived GBM cells. Therefore, there is no indication that the choice of anticonvulsant for seizure control in glioma patients should take treatment with Delta24-RGD into account. Copyright © 2013 John Wiley & Sons, Ltd.
- Open Access
- 13 October 2011
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (10) , e24396
Anatomical Differences Determine Distribution of Adenovirus after Convection-Enhanced Delivery to the Rat Brain
Convection-enhanced delivery (CED) of adenoviruses offers the potential of widespread virus distribution in the brain. In CED, the volume of distribution (Vd) should be related to the volume of infusion (Vi) and not to dose, but when using adenoviruses contrasting results have been reported. As the characteristics of the infused tissue can affect convective delivery, this study was performed to determine the effects of the gray and white matter on CED of adenoviruses and similar sized super paramagnetic iron oxide nanoparticles (SPIO). We convected AdGFP, an adenovirus vector expressing Green Fluorescent Protein, a virus sized SPIO or trypan blue in the gray and white matter of the striatum and external capsule of Wistar rats and towards orthotopic infiltrative brain tumors. The resulting Vds were compared to Vi and transgene expression to SPIO distribution. Results show that in the striatum Vd is not determined by the Vi but by the infused virus dose, suggesting diffusion, active transport or receptor saturation rather than convection. Distribution of virus and SPIO in the white matter is partly volume dependent, which is probably caused by preferential fluid pathways from the external capsule to the surrounding gray matter, as demonstrated by co-infusing trypan blue. Distant tumors were reached using the white matter tracts but tumor penetration was limited. CED of adenoviruses in the rat brain and towards infiltrative tumors is feasible when regional anatomical differences are taken into account while SPIO infusion could be considered to validate proper catheter positioning and predict adenoviral distribution.
- 13 October 2011
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (10) , e24396
Open AccessAnatomical Differences Determine Distribution of Adenovirus after Convection-Enhanced Delivery to the Rat Brain
Convection-enhanced delivery (CED) of adenoviruses offers the potential of widespread virus distribution in the brain. In CED, the volume of distribution (Vd) should be related to the volume of infusion (Vi) and not to dose, but when using adenoviruses contrasting results have been reported. As the characteristics of the infused tissue can affect convective delivery, this study was performed to determine the effects of the gray and white matter on CED of adenoviruses and similar sized super paramagnetic iron oxide nanoparticles (SPIO). We convected AdGFP, an adenovirus vector expressing Green Fluorescent Protein, a virus sized SPIO or trypan blue in the gray and white matter of the striatum and external capsule of Wistar rats and towards orthotopic infiltrative brain tumors. The resulting Vds were compared to Vi and transgene expression to SPIO distribution. Results show that in the striatum Vd is not determined by the Vi but by the infused virus dose, suggesting diffusion, active transport or receptor saturation rather than convection. Distribution of virus and SPIO in the white matter is partly volume dependent, which is probably caused by preferential fluid pathways from the external capsule to the surrounding gray matter, as demonstrated by co-infusing trypan blue. Distant tumors were reached using the white matter tracts but tumor penetration was limited. CED of adenoviruses in the rat brain and towards infiltrative tumors is feasible when regional anatomical differences are taken into account while SPIO infusion could be considered to validate proper catheter positioning and predict adenoviral distribution.
- 1 January 2011
- Vol. 155 (42) , A3400
[Growing skull fracture].
Growing skull fracture (GSF) is a rare complication of cranial trauma in children younger than 3 years. It is characterised by the presence of a dural defect due to which herniation of the brain tissue can develop, with cystic transformation and resulting cerebral damage. A 5-month-old baby girl presented at the emergency department following a fall from the staircase. Upon examination she showed a left parietal subgaleal haematoma and right-sided hemiparesis. MRI examination of the brain showed a skull fracture and dural defect with progressive herniation of the brain tissue. Neurosurgical reconstruction was carried out. GSF is a rare complication of cranial trauma in young children as a result of rupture of the dura and separating fracture edges. This can lead to cerebral damage and early recognition is important. GSF needs to be considered in children younger than 3 years with a (pulsating) subgaleal haematoma. The diagnosis is made by MRI scan of the brain and neurosurgical treatment consists of watertight closure of the dura combined with skull reconstruction.
- 1 January 2011
- Vol. 155 (42) , A3400
[Growing skull fracture].
Growing skull fracture (GSF) is a rare complication of cranial trauma in children younger than 3 years. It is characterised by the presence of a dural defect due to which herniation of the brain tissue can develop, with cystic transformation and resulting cerebral damage. A 5-month-old baby girl presented at the emergency department following a fall from the staircase. Upon examination she showed a left parietal subgaleal haematoma and right-sided hemiparesis. MRI examination of the brain showed a skull fracture and dural defect with progressive herniation of the brain tissue. Neurosurgical reconstruction was carried out. GSF is a rare complication of cranial trauma in young children as a result of rupture of the dura and separating fracture edges. This can lead to cerebral damage and early recognition is important. GSF needs to be considered in children younger than 3 years with a (pulsating) subgaleal haematoma. The diagnosis is made by MRI scan of the brain and neurosurgical treatment consists of watertight closure of the dura combined with skull reconstruction.
- Open Access
- 21 October 2010
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 12 (Supplement) , iv130-iv136
Tumor Models (In Vivo/In Vitro)
INTRODUCTION: Overexpression of STAT3 has been demonstrated in high-grade gliomas. STAT3 is situated at a point of convergence of several signaling pathways implicated in gliomagenesis. However, it is unknown whether STAT3 is capable of inducing tumor formation or progression. We studied STAT3 in a murine glioma model to determine its impact on tumor formation and grade. METHODS: Using the RCAS/Ntv-a system, we expressed constitutively active STAT3 (CA) in mice via somatic cell transfer in the forebrains of mice independently and with PDGFB (known to induce glioma). Mice were euthanized 12 weeks after RCAS vector injection, and the brains were examined for tumor formation. Analysis of proliferation (phosphohistone H3) and activated STAT3 expression (phosphorylated STAT3) was performed. RESULTS: Gliomas formed in 21/29 mice (72%) co-injected with RCAS-STAT3CA + RCAS-PDGFB but only in 11/26 mice (42%) injected with RCAS-PDGFB alone (chi-squared, p = 0.02). High-grade gliomas (HGGs) with classic phenotypic features including necrosis were observed in 14 mice (48%) injected with RCAS-STAT3CA + RCAS-PDGFB but in only five mice (19%) injected with RCAS-PDGFB alone (chi-squared, p = 0.02). No tumors were detected in mice injected with STAT3CA alone. Immunohistochemical analysis revealed pSTAT3 expression localizing to areas adjacent to foci of necrosis in HGGs. The portion of pSTAT3-positive cells in PDGFB + STAT3CA-induced HGGs was significantly higher than that in the PDGFB-induced HGGs (pairwise comparison, p = 0.0002). The mitotic index in HGGs induced by PDGFB + STAT3CA was significantly higher in PDGFB + STAT3CA-induced tumors than in either high- or low-grade PDGFB-induced tumors (pairwise comparison, p = 0.006 and p = 0.004, respectively). CONCLUSION: STAT3 enhances tumor formation in a PDGFB-dependent model of glioma. STAT3 expression also promotes progression to HGG and promotes tumor cell proliferation. Expression of pSTAT3 correlates with areas of necrosis, a cardinal feature of HGGs. These results confirm the relevance of STAT3 signaling in glioma biology.
- 21 October 2010
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 12 (Supplement) , iv130-iv136
Open AccessTumor Models (In Vivo/In Vitro)
INTRODUCTION: Overexpression of STAT3 has been demonstrated in high-grade gliomas. STAT3 is situated at a point of convergence of several signaling pathways implicated in gliomagenesis. However, it is unknown whether STAT3 is capable of inducing tumor formation or progression. We studied STAT3 in a murine glioma model to determine its impact on tumor formation and grade. METHODS: Using the RCAS/Ntv-a system, we expressed constitutively active STAT3 (CA) in mice via somatic cell transfer in the forebrains of mice independently and with PDGFB (known to induce glioma). Mice were euthanized 12 weeks after RCAS vector injection, and the brains were examined for tumor formation. Analysis of proliferation (phosphohistone H3) and activated STAT3 expression (phosphorylated STAT3) was performed. RESULTS: Gliomas formed in 21/29 mice (72%) co-injected with RCAS-STAT3CA + RCAS-PDGFB but only in 11/26 mice (42%) injected with RCAS-PDGFB alone (chi-squared, p = 0.02). High-grade gliomas (HGGs) with classic phenotypic features including necrosis were observed in 14 mice (48%) injected with RCAS-STAT3CA + RCAS-PDGFB but in only five mice (19%) injected with RCAS-PDGFB alone (chi-squared, p = 0.02). No tumors were detected in mice injected with STAT3CA alone. Immunohistochemical analysis revealed pSTAT3 expression localizing to areas adjacent to foci of necrosis in HGGs. The portion of pSTAT3-positive cells in PDGFB + STAT3CA-induced HGGs was significantly higher than that in the PDGFB-induced HGGs (pairwise comparison, p = 0.0002). The mitotic index in HGGs induced by PDGFB + STAT3CA was significantly higher in PDGFB + STAT3CA-induced tumors than in either high- or low-grade PDGFB-induced tumors (pairwise comparison, p = 0.006 and p = 0.004, respectively). CONCLUSION: STAT3 enhances tumor formation in a PDGFB-dependent model of glioma. STAT3 expression also promotes progression to HGG and promotes tumor cell proliferation. Expression of pSTAT3 correlates with areas of necrosis, a cardinal feature of HGGs. These results confirm the relevance of STAT3 signaling in glioma biology.
- 2 June 2010
- Published by Wiley in The Journal of Gene Medicine
- Vol. 12 (7) , 564-571
Objective determination of the oncolytic potency of conditionally‐replicating adenoviruses using mathematical modeling
Background Conditionally-replicating adenoviruses (CRAds) infect and replicate in tumor cells, releasing viral progeny upon lysis of the cell. This is a dynamic and inherently exponential process and, thus, the assessment of CRAds should incorporate these dynamics. In vitro experiments are therefore prone to subjective assessment because no validated assay exists that truly appreciates the dynamics of the process. An objective assay could simplify experiments and reduce the number of CRAd variants required to enter a full preclinical evaluation. Methods We developed a simple and practical mathematical model incorporating easily obtainable parameters of the interaction between replicating viruses and growing tumor cells in vitro and, in the present study, validate this model by fitting the predicted values to experimentally-derived values. Results From the exponential curves of cellular growth and the viral propagation rate in glioma cells, we derive the four parameters needed in this model and show a robust fit to experimental data. Because the initial infection conditions appear to significantly influence the final outcome of CRAd experiments, these conditions are determined using the same cells and correlated with the expression of the primary adenovirus receptor CAR (coxsackie and adenovirus receptor). Conclusions The results obtained shed light upon the method of action of CRAds and provide an objective and practical model and assay for determining and predicting CRAd activity in tumor cells. Copyright © 2010 John Wiley & Sons, Ltd.
- 2 June 2010
- Published by Wiley in The Journal of Gene Medicine
- Vol. 12 (7) , 564-571
Objective determination of the oncolytic potency of conditionally‐replicating adenoviruses using mathematical modeling
Background Conditionally-replicating adenoviruses (CRAds) infect and replicate in tumor cells, releasing viral progeny upon lysis of the cell. This is a dynamic and inherently exponential process and, thus, the assessment of CRAds should incorporate these dynamics. In vitro experiments are therefore prone to subjective assessment because no validated assay exists that truly appreciates the dynamics of the process. An objective assay could simplify experiments and reduce the number of CRAd variants required to enter a full preclinical evaluation. Methods We developed a simple and practical mathematical model incorporating easily obtainable parameters of the interaction between replicating viruses and growing tumor cells in vitro and, in the present study, validate this model by fitting the predicted values to experimentally-derived values. Results From the exponential curves of cellular growth and the viral propagation rate in glioma cells, we derive the four parameters needed in this model and show a robust fit to experimental data. Because the initial infection conditions appear to significantly influence the final outcome of CRAd experiments, these conditions are determined using the same cells and correlated with the expression of the primary adenovirus receptor CAR (coxsackie and adenovirus receptor). Conclusions The results obtained shed light upon the method of action of CRAds and provide an objective and practical model and assay for determining and predicting CRAd activity in tumor cells. Copyright © 2010 John Wiley & Sons, Ltd.
- 26 October 2007
- Published by Wiley in The Journal of Gene Medicine
- Vol. 9 (12) , 1046-1056
AdΔ24 and the p53‐expressing variant AdΔ24‐p53 achieve potent anti‐tumor activity in glioma when combined with radiotherapy
Background The conditionally replicating adenovirus (CRAd) AdΔ24‐p53 replicates selectively in Rb mutant cells, and encodes the p53 suppressor protein. It has shown improved oncolytic potency compared to the parental control AdΔ24. As exogenous p53 has been shown to enhance radiosensitivity, the combination of AdΔ24‐p53 and AdΔ24 with radiotherapy was assessed in vitro and in vivo against the therapy resistant gliomas. Methods In glioma cells, multicellular spheroids and animal xenografts the efficacy of combination therapy was assessed. P53 phosphorylation, induction of apoptosis and viral replication were determined following single or combination therapies. Results In vitro, AdΔ24‐p53 was more effective against glioma cells than the control AdΔ24. Addition of irradiation equally increased the efficacy of both AdΔ24‐p53 and AdΔ24 resulting in improved oncolysis compared to single agent treatment. Radiotherapy did not significantly change the replication kinetics of AdΔ24‐p53 or AdΔ24. No detectable increase in p53 phosphorylation was observed but combination of radiotherapy and AdΔ24‐p53 caused an increase in the percentage of apoptotic cells. In vivo, combination therapy with either AdΔ24 or AdΔ24‐p53 significantly increased the number of mice demonstrating tumor regression (100%) as well as long‐term survival (50%). No differences between viruses were noted. Conclusions Exogenous p53 expression does not appear to increase the synergistic interaction of CRAds combined with radiotherapy. These results however do indicate that radiotherapy provides the time frame in which AdΔ24 and AdΔ24‐p53 can eradicate established tumors that would otherwise escape treatment, and establishes the need to combine these modalities to form an effective anti‐cancer treatment. Copyright © 2007 John Wiley & Sons, Ltd.
- 26 October 2007
- Published by Wiley in The Journal of Gene Medicine
- Vol. 9 (12) , 1046-1056
AdΔ24 and the p53‐expressing variant AdΔ24‐p53 achieve potent anti‐tumor activity in glioma when combined with radiotherapy
Background The conditionally replicating adenovirus (CRAd) AdΔ24‐p53 replicates selectively in Rb mutant cells, and encodes the p53 suppressor protein. It has shown improved oncolytic potency compared to the parental control AdΔ24. As exogenous p53 has been shown to enhance radiosensitivity, the combination of AdΔ24‐p53 and AdΔ24 with radiotherapy was assessed in vitro and in vivo against the therapy resistant gliomas. Methods In glioma cells, multicellular spheroids and animal xenografts the efficacy of combination therapy was assessed. P53 phosphorylation, induction of apoptosis and viral replication were determined following single or combination therapies. Results In vitro, AdΔ24‐p53 was more effective against glioma cells than the control AdΔ24. Addition of irradiation equally increased the efficacy of both AdΔ24‐p53 and AdΔ24 resulting in improved oncolysis compared to single agent treatment. Radiotherapy did not significantly change the replication kinetics of AdΔ24‐p53 or AdΔ24. No detectable increase in p53 phosphorylation was observed but combination of radiotherapy and AdΔ24‐p53 caused an increase in the percentage of apoptotic cells. In vivo, combination therapy with either AdΔ24 or AdΔ24‐p53 significantly increased the number of mice demonstrating tumor regression (100%) as well as long‐term survival (50%). No differences between viruses were noted. Conclusions Exogenous p53 expression does not appear to increase the synergistic interaction of CRAds combined with radiotherapy. These results however do indicate that radiotherapy provides the time frame in which AdΔ24 and AdΔ24‐p53 can eradicate established tumors that would otherwise escape treatment, and establishes the need to combine these modalities to form an effective anti‐cancer treatment. Copyright © 2007 John Wiley & Sons, Ltd.